Please provide your email address to receive an email when new articles are posted on . Originator- and biosimilar-receiving patients with rheumatoid arthritis demonstrated similar disease activity at ...

Please provide your email address to receive an email when new articles are posted on . “Biosimilars offer one potential avenue to decrease spending on biologics, and projections suggest that they ...

The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept ...

The biosimilar SB4 produced response rates equivalent to those associated with etanercept (ETN; Enbrel, Amgen) in patients with severe rheumatoid arthritis (RA) whose disease was not controlled by ...

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster ...

ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

Lupin is introducing Rymti, its first biosimilar in Canada, through its partner Sandoz Canada (Sandoz). Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile ...

The Supreme Court declined to review a petition filed by Novartis’ Sandoz unit that challenged two of Amgen’s patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won’t be a ...

(MENAFN- EIN Presswire) EINPresswire/ -- How Big Is The Adalimumab, Infliximab and Etanercept Biosimilars Market In 2025? The market size of adalimumab, infliximab and etanercept biosimilars has seen ...

(Reuters) - Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study. The drug, CHS-0214, was found to be ...